Table 2 Treatment, relapsing, disease status, death neoplasia and follow up of patients with dermatomyositis
Total (n = 87) | Mi-2 (+) (n = 17) | Mi-2 (−) (n = 70) | P value | |
|---|---|---|---|---|
Treatment | ||||
Methylprednisolone pulse therapy | 37 (42.5) | 10 (58.8) | 27 (38.6) | 0.173 |
IVIG pulse therapy | 24 (27.6) | 7 (41.2) | 17 (24.3) | 0.225 |
Rituximab | 15 (17.2) | 4 (23.5) | 11 (15.7) | 1.000 |
Prednisone | ||||
Current use | 27 (31.0) | 2 (11.8) | 25 (35.7) | 0.079 |
Current dose (mg/day) | 0 [0–5] | 0 [0–0] | 0 [0–10] | 0.042 |
Immunosuppressive drugs | ||||
Current use | 49 (56.3) | 7 (41.2) | 42 (60.0) | 0.182 |
Disease relapsing | 17 (19.5) | 3 (17.6) | 14 (20.0) | 1.000 |
Current disease status | ||||
Disease remission | 29 (33.3) | 10 (58.8) | 19 (27.1) | 0.021 |
Complete clinical response | 49 (56.3) | 6 (35.3) | 43 (61.4) | 0.062 |
Disease activity | 9 (10.3) | 1 (5.9) | 8 (11.4) | 0.682 |
Death | 12 (13.8) | 2 (11.8) | 10 (14.3) | 1.000 |
Neoplasia | 4 (4.6) | 2 (11.8) | 2 (2.9) | 0.170 |
Follow-up | 38 (43.7) | 5 (29.4) | 33 (47.1) | 0.279 |